| Campo DC | Valor | Idioma |
|---|
| dc.contributor.author | Xavier, Mary-Ann Elvina | - |
| dc.contributor.author | Rezende, Fernando | - |
| dc.contributor.author | Almeida, Ricardo Titze de | - |
| dc.contributor.author | Cornelissen, Bart | - |
| dc.date.accessioned | 2022-04-12T14:16:13Z | - |
| dc.date.available | 2022-04-12T14:16:13Z | - |
| dc.date.issued | 2021 | - |
| dc.identifier.citation | Xavier, Mary-Ann et al. BRCAness as a biomarker of susceptibility to PARP inhibitors in glioblastoma multiforme, Biomolecules, v. 11, n. 8, 1188, 2021. DOI: https://doi.org/10.3390/biom11081188. Disponível em: https://www.mdpi.com/2218-273X/11/8/1188. Acesso em: 12 abr. 2022. | pt_BR |
| dc.identifier.uri | https://repositorio.unb.br/handle/10482/43377 | - |
| dc.language.iso | Inglês | pt_BR |
| dc.publisher | MDPI | pt_BR |
| dc.rights | Acesso Aberto | pt_BR |
| dc.title | BRCAness as a biomarker of susceptibility to PARP inhibitors in glioblastoma multiforme | pt_BR |
| dc.type | Artigo | pt_BR |
| dc.subject.keyword | Glioblastoma multiforme | pt_BR |
| dc.subject.keyword | Proteínas | pt_BR |
| dc.rights.license | (CC BY) | pt_BR |
| dc.identifier.doi | https://doi.org/10.3390/biom11081188 | pt_BR |
| dc.description.abstract1 | Glioblastoma multiforme (GBM) is the most common primary brain cancer. GBMs commonly acquire resistance to standard-of-care therapies. Among the novel means to sensitize GBM to DNA-damaging therapies, a promising strategy is to combine them with inhibitors of the DNA damage repair (DDR) machinery, such as inhibitors for poly(ADP-ribose) polymerase (PARP). PARP inhibitors (PARPis) have already shown efficacy and have received regulatory approval for breast, ovarian, prostate, and pancreatic cancer treatment. In these cancer types, after PARPi administration, patients carrying specific mutations in the breast cancer 1 (BRCA1) and 2 (BRCA2) suppressor genes have shown better response when compared to wild-type carriers. Mutated BRCA genes are infrequent in GBM tumors, but their cells can carry other genetic alterations that lead to the same phenotype collectively referred to as ‘BRCAness’. The most promising biomarkers of BRCAness in GBM are related to isocitrate dehydrogenases 1 and 2 (IDH1/2), epidermal growth factor receptor (EGFR), phosphatase and tensin homolog (PTEN), MYC proto-oncogene, and estrogen receptors beta (ERβ). BRCAness status identified by accurate biomarkers can ultimately predict responsiveness to PARPi therapy, thereby allowing patient selection for personalized treatment. This review discusses potential biomarkers of BRCAness for a ‘precision medicine’ of GBM patients. | pt_BR |
| dc.identifier.orcid | https://orcid.org/0000-0001-8125-8879 | pt_BR |
| dc.identifier.orcid | https://orcid.org/0000-0002-5019-4742 | pt_BR |
| dc.description.unidade | Faculdade de Agronomia e Medicina Veterinária (FAV) | - |
| Aparece nas coleções: | Artigos publicados em periódicos e afins
|
